DHR vs. REGN: Danaher vs. Regeneron Pharmaceuticals Stock Comparison

November 11, 2026

How do Danaher (DHR) and Regeneron Pharmaceuticals (REGN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Danaher (DHR) and Regeneron Pharmaceuticals (REGN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but DHR is classified in Life Sciences Tools & Services while REGN is classified in Biotechnology.

Company profile comparison for Danaher (DHR) and Regeneron Pharmaceuticals (REGN)
Profile Item	DHR	REGN
Name	Danaher Corp.	Regeneron Pharmaceuticals, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	161.86 billion USD	93.55 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	December 29, 1978	April 2, 1991
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

DHR

REGN

GSPC

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Danaher (DHR) and Regeneron Pharmaceuticals (REGN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Danaher (DHR) and Regeneron Pharmaceuticals (REGN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Danaher (DHR) and Regeneron Pharmaceuticals (REGN)
Metric	DHR	REGN
Total Return (1Y)	11.88%	40.87%
Total Return (3Y, Annualized)	6.67%	5.15%
Total Return (5Y, Annualized)	-2.05%	8.58%

Risk Profile

Drawdown History

DHR

REGN

GSPC

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Danaher (DHR) and Regeneron Pharmaceuticals (REGN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Danaher (DHR) and Regeneron Pharmaceuticals (REGN)
Metric	DHR	REGN
Volatility (1Y, Annualized)	30.61%	34.08%
Beta (5Y)	0.76	0.10
Max Drawdown (5Y)	-43.31%	-59.69%
Avg. Volume (3M)	3.94M	772.95K

Risk-Adjusted Performance

Risk-Return Positioning

DHR and REGN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Danaher (DHR) and Regeneron Pharmaceuticals (REGN)
Metric	DHR	REGN
Sharpe Ratio (1Y)	0.25	1.07
Sortino Ratio (1Y)	0.35	1.70

Profitability

ROE (TTM)

Both Danaher (DHR) at 8.19% and Regeneron Pharmaceuticals (REGN) at 14.95% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 109.18%
DHR: 8.19%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.95%

Max: 109.18%
REGN: 14.95%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Regeneron Pharmaceuticals (REGN) at 28.51% keeps the most of each sales dollar — above its industry’s net margin range — and Danaher (DHR) at 16.91% also retains a top-quartile share.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.91%

Max: 18.05%
DHR: 16.91%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.51%

REGN: 28.51%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Danaher (DHR) at 21.13% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.13%

Max: 83.12%
DHR: 21.13%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.46%

Max: 83.12%
REGN: 40.46%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Danaher (DHR) and Regeneron Pharmaceuticals (REGN)
Metric	DHR	REGN
ROE (TTM)	8.19%	14.95%
ROA (TTM)	4.06%	7.59%
Net Margin (TTM)	16.91%	28.51%
Operating Margin (TTM)	21.13%	40.46%
Gross Margin (TTM)	59.36%	46.73%

Growth

Revenue Growth

Both Danaher (DHR) at 2.90% and Regeneron Pharmaceuticals (REGN) at 0.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Danaher (DHR) at -4.54% and Regeneron Pharmaceuticals (REGN) at 8.19% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Danaher (DHR) and Regeneron Pharmaceuticals (REGN)
Metric	DHR	REGN
Revenue Growth (YoY)	2.90%	0.99%
Revenue Growth (3Y CAGR)	-2.67%	5.62%
EPS Growth (YoY)	-4.54%	8.19%
EPS Growth (3Y CAGR)	-19.44%	2.77%

Financial Strength

Current Ratio (MRQ)

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Danaher (DHR) at 1.63 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for DHR.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.63

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
DHR: 1.63
Min: 0.10

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.35

Max: 25.13
Q3: 12.13
Median: 5.52
REGN: 3.35
Q1: 2.47
Min: 0.10

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Danaher (DHR) at 0.52 and Regeneron Pharmaceuticals (REGN) at 0.08 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.52

Max: 1.42
Q3: 0.65
DHR: 0.52
Median: 0.15
Q1: 0.02
Min: 0.00

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.08

Max: 1.42
Q3: 0.65
Median: 0.15
REGN: 0.08
Q1: 0.02
Min: 0.00

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Danaher (DHR) and Regeneron Pharmaceuticals (REGN)
Metric	DHR	REGN
Current Ratio (MRQ)	1.63	3.35
Debt / Equity (MRQ)	0.52	0.08
Net Debt / EBITDA	2.68	-1.17

Dividends

Dividend Yield (TTM)

Both Danaher (DHR) at 0.67% and Regeneron Pharmaceuticals (REGN) at 0.41% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67%

DHR: 0.67%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41%

REGN: 0.41%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Danaher (DHR) at 25.17% and Regeneron Pharmaceuticals (REGN) at 8.18% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.17%

DHR: 25.17%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.18%

REGN: 8.18%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Danaher (DHR) and Regeneron Pharmaceuticals (REGN)
Metric	DHR	REGN
Dividend Yield (TTM)	0.67%	0.41%
Dividend Payout Ratio (TTM)	25.17%	8.18%

Valuation

P/E Ratio (TTM)

Both Danaher (DHR) at 38.12 and Regeneron Pharmaceuticals (REGN) at 19.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.12

Max: 85.34
Q3: 43.46
DHR: 38.12
Median: 26.69
Q1: 13.30
Min: 0.07

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.99

Max: 85.34
Q3: 43.46
Median: 26.69
REGN: 19.99
Q1: 13.30
Min: 0.07

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Danaher (DHR) at 6.32 and Regeneron Pharmaceuticals (REGN) at 5.54 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.32

Max: 58.18
Q3: 25.77
Median: 7.30
DHR: 6.32
Q1: 3.01
Min: 0.01

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.54

Max: 58.18
Q3: 25.77
Median: 7.30
REGN: 5.54
Q1: 3.01
Min: 0.01

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Danaher (DHR) at 3.02 and Regeneron Pharmaceuticals (REGN) at 2.71 are valued close to their industries’ norm against book — neither stands out from peers.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.02

Max: 13.53
Q3: 6.54
Median: 3.25
DHR: 3.02
Q1: 1.69
Min: -5.59

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.71

Max: 13.53
Q3: 6.54
Median: 3.25
REGN: 2.71
Q1: 1.69
Min: -5.59

Danaher (DHR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Danaher (DHR) and Regeneron Pharmaceuticals (REGN)
Metric	DHR	REGN
P/E Ratio (TTM)	38.12	19.99
P/S Ratio (TTM)	6.32	5.54
P/B Ratio (MRQ)	3.02	2.71
Free Cash Flow Yield (TTM)	2.93%	2.76%